Previous Close | 4.13 |
1-Year Change | 108.59% |
6-Months Change | 61.96% |
3-Months Change | 40% |
Moving Avg (50d) | 3.8906 |
Moving Avg (200d) | 3.0244 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 0.693B |
Beta (3-Years) | 0.96 |
Revenue Growth (ttm) | -38.19% |
Net Profit Margin (ttm) | -339.32% |
Return On Assets (ttm) | -47.57% |
EPS (ttm) | -0.46 |
PE Ratio (ttm) | -8.98 |
Dividend Yield | % |
Asset Description: | Arbutus Biopharma Corporation |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-07-29 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
4.213 | 4.337 | 4.419 | 4.543 | 4.75 | 4.956 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |